Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ganymed Pharmaceuticals

- PMLiVE

Astellas stays ahead of its FLT3 rivals with EU nod for Xospata

Approval comes after an accelerated review of the drug

- PMLiVE

Seattle Genetics preps filing next year for oral HER2 drug

Company has positive phase 3 data to support filings

- PMLiVE

Astellas’ Xospata scores positive CHMP recommendation

Could become a potential option for hard-to-treat leukaemia

- PMLiVE

AbbVie cures STING fever with Mavupharma acquisition

Joins host of companies pursuing novel mechanism

- PMLiVE

Merck & Co adds to immunotherapy again with $773m Tilos buy

Specialises in TGFβ complex-targeting therapies

- PMLiVE

Keytruda begins pursuit of rivals in small cell lung cancer

Set for competition with Opdivo

- PMLiVE

So far so good for Amgen’s much-anticipated KRAS inhibitor

Promise to hit previously 'undruggable' target

- PMLiVE

AZ invests more in IO with Transgene oncolytic virus deal

Opportunity for combinations with IO pipeline

- PMLiVE

CHMP recommends new Keytruda dosing schedule

Will apply to eight indications across five tumour types

- PMLiVE

Trulicity’s ascent lifts Lilly

Diabetes treatment leads new product growth

Bristol Myers Squibb logo

BMS isn’t phased by Opdivo’s slowing growth – for now

Lung cancer filing withdrawn after FDA reservations

Eli Lilly HQ

Lilly adds to pharma M&A run with $8bn Loxo buy-out

Lilly claims company ahead of more dominant oncology players

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links